Total Funding
14
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
209386
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Acquired by 
Dianthus Therapeutics
- Alison Lawton: ChairPast Role: Kaleido BioSciences, CEO & President
David Scadden: Co-FounderPast Role: Massachusetts General Hospital, Regenerative Medicine
About the Company
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating
hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
